You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Phase III data for Jardiance shows improvement in HFpEF patients

Results from the EMPEROR-Preserved Phase III trial have shown that Jardiance (empagliflozin) demonstrated a 21% relative risk reduction of cardiovascular death or hospitalisation for heart failure in adults with heart failure with preserved ejection fraction (HFpEF).